Silmitasertib (CX-4945), a Clinically Used CK2-Kinase Inhibitor with Additional Effects on GSK3β and DYRK1A Kinases: A Structural Perspective

[Image: see text] A clinical casein kinase 2 inhibitor, CX-4945 (silmitasertib), shows significant affinity toward the DYRK1A and GSK3β kinases, involved in down syndrome phenotypes, Alzheimer’s disease, circadian clock regulation, and diabetes. This off-target activity offers an opportunity for stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Grygier, Przemyslaw, Pustelny, Katarzyna, Nowak, Jakub, Golik, Przemyslaw, Popowicz, Grzegorz M., Plettenburg, Oliver, Dubin, Grzegorz, Menezes, Filipe, Czarna, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10041529/
https://www.ncbi.nlm.nih.gov/pubmed/36883902
http://dx.doi.org/10.1021/acs.jmedchem.2c01887

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10041529/
https://www.ncbi.nlm.nih.gov/pubmed/36883902
http://dx.doi.org/10.1021/acs.jmedchem.2c01887

Ejemplares similares